A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer-Reference-Cited by-同舟云学术

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Published:2023-09-21 Issue:10 Volume:4 Page:1410-1417
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Bobisse Sara,Bianchi Valentina,Tanyi Janos L.,Sarivalasis Apostolos,Missiaglia Edoardo,Pétremand Rémy^ORCID,Benedetti Fabrizio^ORCID,Torigian Drew A.,Genolet Raphael^ORCID,Barras David^ORCID,Michel Alexandra,Mastroyannis Spyridon A.^ORCID,Zsiros Emese,Dangaj Laniti Denarda,Tsourti Zoi,Stevenson Brian J.,Iseli Christian^ORCID,Levine Bruce L.^ORCID,Speiser Daniel E.^ORCID,Gfeller David^ORCID,Bassani-Sternberg Michal^ORCID,Powell Daniel J.^ORCID,June Carl H.^ORCID,Dafni Urania,Kandalaft Lana E.^ORCID,Harari Alexandre^ORCID,Coukos George^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s43018-023-00623-x.pdf

Reference15 articles.

1. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

2. Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640–656 (2022).

3. Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med. 10, eaao5931 (2018).

4. Hanker, L. C. et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 23, 2605–2612 (2012).

5. Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 9, 1092 (2018).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Next-generation cancer vaccines and emerging immunotherapy combinations;Trends in Cancer;2024-08

3. Adoptive T cell therapy for ovarian cancer;Gynecologic Oncology;2024-07

4. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results;Nature Medicine;2024-06-03

5. Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms;Nature Biotechnology;2024-05-07